XML 34 R23.htm IDEA: XBRL DOCUMENT v3.20.2
REVENUE RECOGNITION AND RELATED ALLOWANCES (Tables)
9 Months Ended
Sep. 30, 2020
REVENUE RECOGNITION AND RELATED ALLOWANCES  
Schedule of disaggregation of revenue and revenue recognized

Three Months Ended

Nine Months Ended

Products and Services

September 30, 

September 30, 

September 30, 

September 30, 

(in thousands)

    

2020

    

2019

    

2020

    

2019

    

Sales of generic pharmaceutical products

$

37,712

$

31,753

$

108,607

$

99,452

Sales of branded pharmaceutical products

 

12,411

 

16,605

 

32,201

 

48,300

Sales of contract manufactured products

 

2,152

 

2,376

 

7,026

 

8,499

Royalties from licensing agreements

 

339

 

268

 

1,120

 

594

Product development services

 

289

 

75

 

1,751

 

806

Other(1)

 

76

 

260

 

518

 

930

Total net revenues

$

52,979

$

51,337

$

151,223

$

158,581

(1)

Primarily includes laboratory services and royalties on sales of contract manufactured products.

The following table depicts revenue recognized during the following periods:

Three Months Ended

Nine Months Ended

Timing of Revenue Recognition

September 30, 

September 30, 

September 30, 

September 30, 

(in thousands)

    

2020

    

2019

    

2020

    

2019

    

Performance obligations transferred at a point in time

$

52,690

$

51,262

$

149,472

$

157,775

Performance obligations transferred over time

 

289

 

75

 

1,751

 

806

Total

$

52,979

$

51,337

$

151,223

$

158,581

Schedule of accruals and allowances

The following table summarizes activity in the consolidated balance sheets for accruals and allowances for the nine months ended September 30, 2020 and 2019, respectively:

Accruals for Chargebacks, Returns, and Other Allowances

Administrative

Prompt

Government

Fees and Other

Payment

(in thousands)

    

Chargebacks

    

Rebates

    

Returns

    

Rebates

    

Discounts

Balance at December 31, 2018 (1)

$

39,007

$

8,974

$

12,552

$

7,353

$

2,009

Accruals/Adjustments

 

187,843

 

12,723

 

13,392

 

27,476

 

7,962

Credits Taken Against Reserve

 

(188,504)

(12,513)

 

(9,999)

 

(26,927)

 

(7,714)

Balance at September 30, 2019 (1)

$

38,346

$

9,184

$

15,945

$

7,902

$

2,257

Balance at December 31, 2019 (1)

$

49,882

$

8,901

$

16,595

$

8,281

$

2,549

Accruals/Adjustments

 

288,538

 

14,288

 

22,744

 

27,383

 

10,248

Credits Taken Against Reserve

 

(262,531)

(11,511)

 

(16,089)

 

(27,287)

 

(9,442)

Balance at September 30, 2020 (1)

$

75,889

$

11,678

$

23,250

$

8,377

$

3,355

(1)Chargebacks are included as an offset to accounts receivable, net of chargebacks and other allowances in the unaudited condensed consolidated balance sheets. Administrative Fees and Other Rebates and Prompt Payment Discounts are included as an offset to accounts receivable, net of chargebacks and other allowances or accrued expenses and other in the unaudited condensed consolidated balance sheets. Returns are included in returned goods reserve in the unaudited condensed consolidated balance sheets. Government Rebates are included in accrued government rebates in the unaudited condensed consolidated balance sheets.
Schedule of customer concentration

Three Months Ended

Nine Months Ended

September 30, 

September 30, 

September 30, 

September 30, 

    

2020

    

2019

    

2020

    

    

2019

    

Customer 1

30

%

34

%

31

%

33

%

Customer 2

25

%

24

%

24

%

24

%

Customer 3

19

%

23

%

19

%

24

%